As well, mutations in the Runt-related transcription factor 1 (RUNX-1) binding site in the PD-1 gene resulted in defective PD-1-mediated inhibition of IFN-c production in MS patients [14]. This evidence concerns the gene RUNX1 and myeloid sarcoma.